Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The study team's principal interest is to address the question, "Will prophylactic treatment
with mesalamine reduce the incidence and severity of immune-related diarrhea occurring
secondarily to treatment with ipi/nivo?"